MNG1243
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.235
- PANCREAS_BETA_CELLS+0.227
- MYOGENESIS+0.195
- COAGULATION+0.189
- KRAS_SIGNALING_DN+0.176
- IL6_JAK_STAT3_SIGNALING+0.156
- APICAL_SURFACE+0.120
- ALLOGRAFT_REJECTION+0.079
- XENOBIOTIC_METABOLISM+0.035
- ESTROGEN_RESPONSE_LATE+0.022
Top 10 suppressed
- MYC_TARGETS_V1-0.472
- MTORC1_SIGNALING-0.468
- G2M_CHECKPOINT-0.459
- PROTEIN_SECRETION-0.422
- CHOLESTEROL_HOMEOSTASIS-0.404
- UNFOLDED_PROTEIN_RESPONSE-0.380
- E2F_TARGETS-0.378
- MYC_TARGETS_V2-0.359
- MITOTIC_SPINDLE-0.318
- ANDROGEN_RESPONSE-0.304
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1245 | — | — | 0.886 |
| 2 | MNG1159 | — | — | 0.886 |
| 3 | MNG441 | — | — | 0.883 |
| 4 | MNG1230 | — | — | 0.880 |
| 5 | MNG1258 | — | — | 0.877 |
| 6 | MNG655 | — | — | 0.869 |
| 7 | MNG60 | — | — | 0.869 |
| 8 | SRR1472663 | GTEX | — | 0.867 |
| 9 | SJEPD014_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.862 |
| 10 | MNG1148 | — | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.235 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.227 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.195 | Inavolisib | — uncovered |
| COAGULATION | 0.189 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.176 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.156 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.079 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.035 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.022 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.015 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.008 | Inavolisib | — uncovered |